{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotype&page=5",
    "query": {
      "intervention": "Genotype",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 821,
    "total_pages": 83,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotype&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotype&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T20:02:28.255Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03512210",
      "title": "Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "HIV-1-infection",
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir/Velpatasvir (SOF/VEL)",
          "type": "DRUG"
        },
        {
          "name": "Minimal Monitoring (MINMON) Strategy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2018-10-22",
      "completion_date": "2021-02-28",
      "has_results": true,
      "last_update_posted_date": "2022-02-04",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03512210"
    },
    {
      "nct_id": "NCT00708773",
      "title": "Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2006-02",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-01-04",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00708773"
    },
    {
      "nct_id": "NCT01247194",
      "title": "A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Genotype 1 Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "PPI-461",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Presidio Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-10",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-02-03",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • San Francisco, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01247194"
    },
    {
      "nct_id": "NCT01080222",
      "title": "A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "telaprevir",
          "type": "DRUG"
        },
        {
          "name": "VX-222",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        },
        {
          "name": "peginterferon-alfa-2a",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 152,
      "start_date": "2010-08",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2020-09-30",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01080222"
    },
    {
      "nct_id": "NCT00446355",
      "title": "Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clostridium Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2007-02",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2009-04-14",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00446355"
    },
    {
      "nct_id": "NCT00546715",
      "title": "A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 95,
      "start_date": "2007-11",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 7,
      "location_summary": "Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546715"
    },
    {
      "nct_id": "NCT04664478",
      "title": "Gene First Approach to Connective Tissue Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Abnormal Elastogenesis",
        "Vascular Diseases",
        "Connective Tissue Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Years to 100 Years"
      },
      "enrollment_count": 32,
      "start_date": "2021-04-22",
      "completion_date": "2025-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04664478"
    },
    {
      "nct_id": "NCT02955121",
      "title": "IU Health Krannert Personalized Medicine Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Prescriber Access to Genetic Information",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2016-11",
      "completion_date": "2020-01-15",
      "has_results": false,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955121"
    },
    {
      "nct_id": "NCT00216281",
      "title": "Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Clozapine augmented with atomoxetine up to 40 mg or placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 126,
      "start_date": "2005-09",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2013-03-26",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00216281"
    },
    {
      "nct_id": "NCT00987337",
      "title": "Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Filibuvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2009-11",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-01-27",
      "last_synced_at": "2026-10-17T20:02:28.255Z",
      "location_count": 30,
      "location_summary": "Anaheim, California • Coronado, California • La Jolla, California + 22 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mather",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00987337"
    }
  ]
}